Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics

• Autori principali: Haibin Wu (Autore), Meng Wang (Autore), Bo Dai (Autore), Yanmin Zhang (Autore), Ying Yang (Autore), Qiao Li (Autore), Mingyue Duan (Autore), Xi Zhang (Autore), Xiaomei Wang (Autore), Anmao Li (Autore), Liyu Zhang (Autore)
• Natura: Libro
• Pubblicazione: Taylor & Francis Group, 2017-01-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Since conventional chemotherapy for acute myeloid leukemia (AML) has its limitations, a theranostic platform with targeted and efficient drug transport is in demand. In this study, we developed the first CD123 (AML tumor marker) aptamers and designed a novel CD123-aptamer-mediated targeted drug trai...